Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome: a debilitating genetic disorder that occurs in more than one in every 15,000 live births.
from The Medical News http://ift.tt/1zF5t0F
from The Medical News http://ift.tt/1zF5t0F
No comments:
Post a Comment